Details

Details

Title Androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high risk prostate cancer: a phase III randomized trial

IRB RTOG0924

CC CC16-475

Hospital Fairview, Florida Weston, Main Campus, Mansfield, Strongsville

Phase Phase 3

Disease Prostate

Description

Description

Primary Objective

Demonstrate that prophylactic neoadjuvant androgen deprivation therapy (NADT) and whole-pelvic radiation therapy (WPRT) will result in improvement in overall survival (OS) in patients with "unfavorable" intermediate risk or "favorable" high risk prostate cancer compared to NADT and high dose prostate and seminal vesicle (SV) radiation therapy (P + SV RT) using intensity modulated radiotherapy (IMRT) or EBRT with a high dose rate (HDR) or a permanent prostate (radioactive seed) implant (PPI) boost

Secondary Objectives

  1. Demonstrate that prophylactic WPRT improves biochemical control ("Phoenix definition").

    Patients not meeting these PSA criteria (Phoenix Definition) for failure who undergo salvage therapies (such as ADT, radical prostatectomy or brachytherapy, or Cryosurgery) should also be declared as failures at the time a positive biopsy is obtained or salvage therapy is administered, whichever comes first.

  2. Distant metastasis (DM) free-survival, defined as imaging documented evidence of distant spread of disease;
  3. Cause specific survival (CSS) will be defined as death from prostate cancer after biochemical failure followed by the development of metastatic disease followed by the development of castration resistant prostate cancer (CRPC).
  4. Compare acute and late treatment adverse events between patients receiving NADT + WPRT versus NADT + P & SV RT;
  5. Determine whether health related quality of life (HRQOL) as measured by the Expanded Prostate Cancer Index Composite (EPIC) significantly worsens with increasing aggressiveness of treatment (i.e. Arm 2, NADT + WPRT);
  6. Determine whether more aggressive treatment (Arm 2, NADT + WPRT) is associated with a greater increase in fatigue (PROMIS Fatigue Short Form) from baseline to last week of treatment and a greater increase in circulating inflammatory markers (IL-1, IL-1ra, IL-6, TNFalpha, and C-reactive Protein);
  7. Demonstrate an incremental gain in OS and CSS with more aggressive therapy that outweighs any detriments in the primary generic domains of HRQOL (i.e., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression); this will be reported as the Quality Adjusted Freedom From Progression Year (QAFFPY) and as the Quality Adjusted Life Year (QALY);
  8. Determine whether changes in fatigue from baseline to the next three time points (week prior to radiation therapy, last week of treatment, and 3 months after treatment) are associated with changes in circulating cytokines, mood, sleep, and daily activities across the same time points.
  9. Collect paraffin-embedded tissue blocks, plasma, whole blood, and urine for planned and future translational research analyses.
Inclusion Criteria

Inclusion Criteria

  1. Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate to high risk for recurrence as determined by one of the following combinations:
    • Gleason score 7-10 + T1c-T2b (palpation) + PSA < 50 ng/ml (includes intermediate and high risk patients);
    • Gleason score 6 + T2c-T4 (palpation) + PSA < 50 ng/ml-ORGleason score 6 + ≥ 50% (positive) biopsies + PSA < 50 ng/ml;
    • Gleason score 6 + T1c-T2b (palpation) + PSA > 20 ng/ml.
  2. Patients previously diagnosed with low risk prostate cancer undergoing active surveillance who are re-biopsied and found to have unfavorable intermediate risk disease or favorable high risk disease according to the protocol criteria are eligible for enrollment within 180 days of the repeat biopsy procedure.
  3. History/physical examination (to include at a minimum digital rectal examination of the prostate and examination of the skeletal system and abdomen) within 90 days prior to registration.
  4. Clinically negative lymph nodes as established by imaging (pelvic +/- abdominal CT or MR), (but not by nodal sampling, or dissection) within 90 days prior to registration. Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are ≤ 1.5 cm.
  5. No evidence of bone metastases (M0) on bone scan within 120 days prior to registration. (Na F PET/CT is an acceptable substitute). Equivocal bone scan findings are allowed if plain films (or CT or MRI) are negative for metastasis.
  6. Baseline serum PSA value performed with an FDA-approved assay (e.g., Abbott, Hybritech) within 120 days prior to registration. Study entry PSA should not be obtained during the following time frames: (1) 10-day periodfollowing prostate biopsy; (2) following initiation of hormonal therapy; (3) within 30 days after discontinuation of finasteride; (4) within 90 days after discontinuation of dutasteride.
  7. Zubrod Performance Status 0-1(unless otherwise specified);
  8. Age ≥ 18;
  9. CBC/differential obtained within 60 days prior to registration on study, with adequate bone marrow function defined as follows:
    • Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3;
    • Platelets ≥ 100,000 cells/mm3;
    • Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.);
  10. Patient must be able to provide study specific informed consent prior to study entry.
Exclusion Criteria

Exclusion Criteria

  1. Prior invasive (except non-melanoma skin cancer) malignancy unless disease-free for a minimum of 3 years (1095 days) not in the pelvis. (For example, carcinoma in situ of the oral cavity is permissible; however, patients with prior history of bladder cancer are not allowed). Prior hematological (e.g., leukemia, lymphoma, myeloma) malignancy not allowed.
  2. Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
  3. Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
  4. Previous hormonal therapy, such as LHRH agonists (e.g., leuprolide, goserelin, buserelin, triptorelin) or LHRH antagonist (e.g. degarelix), anti-androgens (e.g., flutamide, bicalutamide, cyproterone acetate), estrogens (e.g., DES), or surgical castration (orchiectomy)
    • Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both LHRH agonist and oral anti-androgen) is ≤ 45 days prior to the date of registration. Please refer to Section 7.1.1 for timing of oral antiandrogen administration with the LHRH agonist.
  5. Use of finasteride within 30 days prior to registration
  6. Use of dutasteride or dutasteride/tamsulosin (Jalyn) within 90 days prior to registration
  7. Previous or concurrent cytotoxic chemotherapy for prostate cancer; note that prior chemotherapy for a different cancer is allowable. See Section 3.2.1.
  8. Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy fields
  9. Severe, active co-morbidity, defined as follows:
    • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
    • Transmural myocardial infarction within the last 6 months
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
    • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects or severe liver dysfunction
    • Acquired immune deficiency syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immuno-compromised patients.
  10. Patients who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
  11. Prior allergic reaction to the hormones involved in this protocol
  12. Patients status post a negative lymph node dissection are not eligible